Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients.
Nine patients with malignant brain tumors were treated with intratumoral infusion of lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). LAK cells were generated from macrophage-depleted peripheral blood lymphocytes by culturing with IL-2 for 4 days. The resulting LAK cells showed strong cytotoxic activity against tumor target cells. Three patients received sufficient LAK cells (> or = 5.76 x 10(8)) to show partial tumor response by computed tomography and clinical signs. No severe neurological side effects occurred in any patient. Intratumoral administration of LAK cells and IL-2 can be effective in patients with malignant brain tumors.
Ibayashi
Y
Y
Department of Neurosurgery, Sapporo Medical College.
Yamaki
T
T
Kawahara
T
T
Daibo
M
M
Kubota
T
T
Uede
T
T
Tanabe
S
S
Hashi
K
K
D000328:Adult; D001921:Brain / Q000187:drug effects* / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D001932:Brain Neoplasms / Q000145:classification / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D003399:Craniotomy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D008264:Macrophages / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D007376:Interleukin-2